Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells ; volume:16 ; number:1 ; day:26 ; month:5 ; year:2016 ; pages:1-16 ; date:12.2016
BMC cancer ; 16, Heft 1 (26.5.2016), 1-16, 12.2016
- Creator
-
Somasundaram, Veena
- Contributor
-
Hemalatha, Sreelatha K.
Pal, Krishnendu
Sinha, Sutapa
Nair, Asha S.
Mukhopadhyay, Debabrata
Srinivas, Priya
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2372-4
- URN
-
urn:nbn:de:1111-2016052815596
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Somasundaram, Veena
- Hemalatha, Sreelatha K.
- Pal, Krishnendu
- Sinha, Sutapa
- Nair, Asha S.
- Mukhopadhyay, Debabrata
- Srinivas, Priya
- SpringerLink (Online service)
Other Objects (12)
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Pre‐clinical validation of a selective anti‐cancer stem cell therapy for Numb‐deficient human breast cancers
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Clearing the HIV reservoir by transplanting CCR5 deficient stem cells
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Pre‐clinical validation of a selective anti‐cancer stem cell therapy for Numb‐deficient human breast cancers
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Clearing the HIV reservoir by transplanting CCR5 deficient stem cells
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Pre‐clinical validation of a selective anti‐cancer stem cell therapy for Numb‐deficient human breast cancers
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy